Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;101(3):356-61.
doi: 10.1113/EP085148.

The molecular actions of oestrogen in the regulation of vascular health

Charlotte W Usselman  1 , Nina S Stachenfeld  2   3   4 , Jeffrey R Bender  5   6   7
Affiliations
Review

The molecular actions of oestrogen in the regulation of vascular health

Charlotte W Usselman et al. Exp Physiol. 2016 Mar.

Abstract

What is the topic of this review? This review summarizes the beneficial actions of oestrogen on the vasculature, highlighting both molecular mechanisms and functional outcomes. What advances does it highlight? The net effect of oestrogen on the vascular health of women continues to be debated. Recent advances have provided strong evidence for the role of membrane-bound oestrogen receptors in the maintenance of normal endothelial function. On a broader scale, functional outcomes of oestrogen actions on the vasculature may mediate the reduced risk of cardiovascular disease in premenopausal women. The conflicting implications of the large-scale clinical menopausal hormone therapy trials in humans versus the findings of studies on experimental animals underscore the limitations within our understanding of the molecular actions of oestrogen. However, recent research has provided improved insight into the actions of oestrogen on the endothelium and vascular smooth muscle. This review outlines the actions of oestrogen as it contributes to vascular structure, function and health.

PubMed Disclaimer

References

    1. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA: The Journal of the American Medical Association. 273:199–208. - PubMed
    1. ANDERSON GL, LIMACHER M, ASSAF AR, BASSFORD T, BERESFORD SA, BLACK H, BONDS D, BRUNNER R, BRZYSKI R, CAAN B, CHLEBOWSKI R, CURB D, GASS M, HAYS J, HEISS G, HENDRIX S, HOWARD BV, HSIA J, HUBBELL A, JACKSON R, JOHNSON KC, JUDD H, KOTCHEN JM, KULLER L, LACROIX AZ, LANE D, LANGER RD, LASSER N, LEWIS CE, MANSON J, MARGOLIS K, OCKENE J, O’SULLIVAN MJ, PHILLIPS L, PRENTICE RL, RITENBAUGH C, ROBBINS J, ROSSOUW JE, SARTO G, STEFANICK ML, VAN HL, WACTAWSKI-WENDE J, WALLACE R, WASSERTHEIL-SMOLLER S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA: The Journal of the American Medical Association. 2004;291:1701–1712. - PubMed
    1. ARNAL JF, FONTAINE C, BILLON-GALES A, FAVRE J, LAURELL H, LENFANT F, GOURDY P. Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol. 2010;30:1506–1512. - PubMed
    1. BARRETT-CONNOR E, GRADY D, SASHEGYI A, ANDERSON PW, COX DA, HOSZOWSKI K, RAUTAHARJU P, HARPER KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA: The Journal of the American Medical Association. 2002;287:847–857. - PubMed
    1. BARRETT-CONNOR E, MOSCA L, COLLINS P, GEIGER MJ, GRADY D, KORNITZER M, MCNABB MA, WENGER NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137. - PubMed

Publication types

LinkOut - more resources